Loading
BCL11B (B-cell lymphoma/leukaemia 11B) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Vulvar cancer, Non-Hodgkin lymphoma, Skin cancer and 5 more.
Key regulator of both differentiation and survival of T-lymphocytes during thymocyte development in mammals. Essential in controlling the responsiveness of haematopoietic stem cells to chemotactic signals by modulating the expression of the receptors CCR7 and CCR9, which direct the movement of progenitor cells from the bone marrow to the thymus. Is a regulator of IL2 promoter and enhances IL2 expression in activated CD4(+) T-lymphocytes.
Open Targets scores its association with cancer at 0.73 (direct and indirect evidence; datatypes literature 0.94, animal model 0.46, genetic association 0.55, somatic mutation 0.86). IntOGen calls it a driver in 3 cohorts (3 activating, 0 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Glioblastoma Multiforme, Vulva/Vagina.
In plain words · BCL11B (B-cell lymphoma/leukaemia 11B) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Vulvar cancer, Non-Hodgkin lymphoma, Skin cancer and 5 more.
BCL11B (B-cell lymphoma/leukaemia 11B) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Vulvar cancer, Non-Hodgkin lymphoma, Skin cancer and 5 more.
Key regulator of both differentiation and survival of T-lymphocytes during thymocyte development in mammals.
No product in this corpus aims at BCL11B yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
First described 2001. Earliest sequence paper UniProt cites for the protein: Satterwhite et al, Blood, 2001, "The BCL11 gene family: involvement of BCL11A in lymphoid malignancies". Source.
Sources: HGNC HGNC:13222 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9C0K0 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000127152 (association with cancer (MONDO_0004992) 0.73; per-cancer scores at or above 0.5: colorectal cancer 0.51, melanoma 0.52, non-Hodgkin lymphoma 0.56, skin cancer 0.56, breast cancer 0.52, lung cancer 0.50 (GraphQL API, CC0)); IntOGen BCL11B (driver in 3 cohorts (Act 3, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Key regulator of both differentiation and survival of T-lymphocytes during thymocyte development in mammals. Essential in controlling the responsiveness of haematopoietic stem cells to chemotactic signals by modulating the expression of the receptors CCR7 and CCR9, which direct the movement of progenitor cells from the bone marrow to the thymus. Is a regulator of IL2 promoter and enhances IL2 expression in activated CD4(+) T-lymphocytes. Tumour-suppressor that represses transcription through direct, TFCOUP2-independent binding to a GC-rich response element. May also function in the P53-signalling pathway. Location: Nucleus (UniProt). Locus 14q32.2 (HGNC).
Query for this target: (TITLE:"BCL11B" OR ABSTRACT:"BCL11B" OR TITLE:"BCL11 transcription factor B" OR ABSTRACT:"BCL11 transcription factor B" OR TITLE:"B-cell lymphoma/leukemia 11B" OR ABSTRACT:"B-cell lymphoma/leukemia 11B" OR TITLE:"CTIP-2" OR ABSTRACT:"CTIP-2" OR TITLE:"CTIP2" OR ABSTRACT:"CTIP2" OR TITLE:"hRIT1-alpha" OR ABSTRACT:"hRIT1-alpha") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BCL11B, not a curated reading list.
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Lung cancer (all types).
Shares Leukaemia (all types), IntOGen, Lung cancer (all types), Breast cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Lung cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Breast cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Lung cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), Breast cancer (all types), Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Lung cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Lung cancer (all types).